Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.